Acute coronary syndrome as the first manifestation of essential thrombocythaemia: A challenge for cardiologists. 2020

Francisco Javier Garcipérez de Vargas, and María Antonia Ramírez Ariza, and Pablo Sánchez Calderón, and Pedro Mellado Delgado, and Pablo García García, and José Javier Gómez Barrado
Servicio de Cardiología, Hospital Don Benito-Villanueva de la Serena, Don Benito, Badajoz, España. Electronic address: fj.garci@hotmail.com.

We present the case is presented of an acute coronary syndrome in a 30-year-old patient with essential thrombocythaemia. Acute coronary syndromes occur in 9% of cases in these patients, and their management constitutes a challenge for the cardiologist, specifically in terms of choosing the most appropriate antiplatelet therapy and its duration, taking into account that these patients have a high thrombotic risk, as well as a considerable haemorrhagic risk.

UI MeSH Term Description Entries
D008297 Male Males
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013920 Thrombocythemia, Essential A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets. Hemorrhagic Thrombocythemia,Thrombocythemia, Hemorrhagic,Thrombocythemia, Idiopathic,Thrombocythemia, Primary,Primary Thrombocythemia,Thrombocytosis, Autosomal Dominant,Thrombocytosis, Primary,Autosomal Dominant Thrombocytoses,Autosomal Dominant Thrombocytosis,Dominant Thrombocytoses, Autosomal,Dominant Thrombocytosis, Autosomal,Essential Thrombocythemia,Essential Thrombocythemias,Hemorrhagic Thrombocythemias,Idiopathic Thrombocythemia,Idiopathic Thrombocythemias,Primary Thrombocythemias,Primary Thrombocytoses,Primary Thrombocytosis,Thrombocythemias, Essential,Thrombocythemias, Hemorrhagic,Thrombocythemias, Idiopathic,Thrombocythemias, Primary,Thrombocytoses, Autosomal Dominant,Thrombocytoses, Primary
D013927 Thrombosis Formation and development of a thrombus or blood clot in BLOOD VESSELS. Atherothrombosis,Thrombus,Blood Clot,Blood Clots,Thromboses
D054058 Acute Coronary Syndrome An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION. Acute Coronary Syndromes,Coronary Syndrome, Acute,Coronary Syndromes, Acute,Syndrome, Acute Coronary,Syndromes, Acute Coronary

Related Publications

Francisco Javier Garcipérez de Vargas, and María Antonia Ramírez Ariza, and Pablo Sánchez Calderón, and Pedro Mellado Delgado, and Pablo García García, and José Javier Gómez Barrado
November 2013, Journal of cardiology cases,
Francisco Javier Garcipérez de Vargas, and María Antonia Ramírez Ariza, and Pablo Sánchez Calderón, and Pedro Mellado Delgado, and Pablo García García, and José Javier Gómez Barrado
March 2012, Deutsche medizinische Wochenschrift (1946),
Francisco Javier Garcipérez de Vargas, and María Antonia Ramírez Ariza, and Pablo Sánchez Calderón, and Pedro Mellado Delgado, and Pablo García García, and José Javier Gómez Barrado
January 2017, Kardiologia polska,
Francisco Javier Garcipérez de Vargas, and María Antonia Ramírez Ariza, and Pablo Sánchez Calderón, and Pedro Mellado Delgado, and Pablo García García, and José Javier Gómez Barrado
January 2014, Nederlands tijdschrift voor geneeskunde,
Francisco Javier Garcipérez de Vargas, and María Antonia Ramírez Ariza, and Pablo Sánchez Calderón, and Pedro Mellado Delgado, and Pablo García García, and José Javier Gómez Barrado
July 2019, BMJ case reports,
Francisco Javier Garcipérez de Vargas, and María Antonia Ramírez Ariza, and Pablo Sánchez Calderón, and Pedro Mellado Delgado, and Pablo García García, and José Javier Gómez Barrado
January 2018, Archivos de bronconeumologia,
Francisco Javier Garcipérez de Vargas, and María Antonia Ramírez Ariza, and Pablo Sánchez Calderón, and Pedro Mellado Delgado, and Pablo García García, and José Javier Gómez Barrado
September 2019, Revista portuguesa de cardiologia,
Francisco Javier Garcipérez de Vargas, and María Antonia Ramírez Ariza, and Pablo Sánchez Calderón, and Pedro Mellado Delgado, and Pablo García García, and José Javier Gómez Barrado
February 1996, Lancet (London, England),
Francisco Javier Garcipérez de Vargas, and María Antonia Ramírez Ariza, and Pablo Sánchez Calderón, and Pedro Mellado Delgado, and Pablo García García, and José Javier Gómez Barrado
July 2008, Kardiologia polska,
Francisco Javier Garcipérez de Vargas, and María Antonia Ramírez Ariza, and Pablo Sánchez Calderón, and Pedro Mellado Delgado, and Pablo García García, and José Javier Gómez Barrado
January 2017, Tanaffos,
Copied contents to your clipboard!